Facilitating Anti-infective Drug Development for Neonates and Young Infants — September 15, 2016

Speakers and Panelists

John Alexander, MD, MPH
Deputy Director
Division of Pediatric and Maternal Health (DPMH), Office of Drug Evaluation IV (ODEIV), CDER
Food and Drug Administration, Silver Spring, Maryland

Danny Benjamin, MD, PhD, MPH
Kiser-Arena Distinguished Professor of Pediatrics
Chair, Pediatric Trials Network
Faculty Associate Director, Duke Clinical Research Institute
Duke University, Durham, North Carolina

John Bradley, MD
Professor and Chief of the Division of Infectious Diseases in the Department of Pediatrics
University of California, San Diego

John Farley, MD, MPH
Deputy Director
Office of Antimicrobial Products (OAP), CDER
Food and Drug Administration, Silver Spring, Maryland

William Hope, PhD
Professor of Therapeutics and Infectious Diseases
University of Liverpool, Liverpool, UK

Laura Kovanda
Director, Global Development Project Leader
Astellas Pharma Global Development, Inc., Northbrook, IL

Susan McCune, MD, M.A.Ed.
Deputy Director
Office of Translational Sciences, CDER
Food and Drug Administration, Silver Spring, Maryland

Lily Mulugeta, Pharm.D.
Lead Scientist for Pediatrics
Division of Pharmacometrics, Office of Clinical Pharmacology, CDER
Food and Drug Administration, Silver Spring, Maryland
Sumathi Nambiar, MD, MPH
Director
Division of Anti-infective Products (DAIP), OAP, CDER
Food and Drug Administration, Silver Spring, Maryland

Gary Noel, MD
Senior Director in the Child Health Innovation Leadership Department (CHILD)
Johnson and Johnson, Raritan, New Jersey

Christopher Rubino, Pharm.D.
Executive Vice President of Pharmacometrics
Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York

Brian Smith, MD, MHS, MPH
Professor of Pediatrics
Steering Committee Member, Pediatric Trials Network
Duke Clinical Research Institute
Duke University, Durham, North Carolina

Thomas Smith, MD
Clinical Team Leader, Division of Anti-Infective Products
OAP, CDER, FDA

Mark Turner, PhD
Senior Lecturer in Neonatology (Clinical)
University of Liverpool, Liverpool, UK

Yuliya Yasinskaya, MD
Medical Officer, Division of Anti-Infective Products
OAP, CDER, FDA

Anne Zajicek, MD, Pharm.D.
Chief, Obstetric and Pediatric Pharmacology and Therapeutics Branch
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health, Bethesda, Maryland
Disclosures

Dr. Bradley’s employer, the Regents of the University of California, receives research grant support from AstraZeneca, Alios, Cubist/Merck, Allergan, Cempra, The Medicines Company, Theravance, as well as the NICHD, and the RCHSD Foundation. The Regents provide consultation to Allergan, Alios, AstraZeneca, Nabriva and Zavante. The University of California may have other interactions with regulated industry of which Dr. Bradley is not aware.

Dr. Hope has received research funding from Pfizer, Gilead, Astellas, AiCuris, Amplyx, Spero Therapeutics and F2G, and acted as a consultant and/or given talks for Pfizer, Basilea, Astellas, F2G, Nordic Pharma, Medicines Company, Amplyx, Mayne Pharma, Spero Therapeutics, Auspherix, Cardeas and Pulmocide.

Dr. Rubino is a full time employee of the Institute for Clinical Pharmacodynamics and is currently the Executive Vice President of Pharmacometrics at ICPD.

Dr. Noel is a full-time employee of Johnson & Johnson.

Dr. Kovanda is a full-time employee of Astellas Pharma Global Development, Inc.